Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Complementary function of the two catalytic domains of APOBEC3G.

Navarro F, Bollman B, Chen H, König R, Yu Q, Chiles K, Landau NR.

Virology. 2005 Mar 15;333(2):374-86.

2.

New insights into the role of Vif in HIV-1 replication.

Schröfelbauer B, Yu Q, Landau NR.

AIDS Rev. 2004 Jan-Mar;6(1):34-9. Review.

PMID:
15168739
3.

HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.

Kremer M, Schnierle BS.

Curr HIV Res. 2005 Oct;3(4):339-44. Review.

PMID:
16250885
4.

The viral infectivity factor (Vif) of HIV-1 unveiled.

Rose KM, Marin M, Kozak SL, Kabat D.

Trends Mol Med. 2004 Jun;10(6):291-7. Review.

PMID:
15177194
5.

APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.

Franca R, Spadari S, Maga G.

Med Sci Monit. 2006 May;12(5):RA92-8. Review.

PMID:
16641889
6.

Recent insights into HIV-1 Vif.

Navarro F, Landau NR.

Curr Opin Immunol. 2004 Aug;16(4):477-82. Review.

PMID:
15245742
7.

[The innate antiretroviral defense of human cells, based on the DNA editing].

Pupecka M, Pacak A.

Postepy Biochem. 2006;52(3):247-52. Review. Polish.

PMID:
17201059
8.

Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif.

Romani B, Engelbrecht S, Glashoff RH.

Arch Virol. 2009;154(10):1579-88. doi: 10.1007/s00705-009-0481-y. Epub 2009 Aug 12. Review.

PMID:
19669862
9.

Death by deamination: a novel host restriction system for HIV-1.

Goff SP.

Cell. 2003 Aug 8;114(3):281-3. Review.

10.

Lentiviral Vif: viral hijacker of the ubiquitin-proteasome system.

Ehrlich ES, Yu XF.

Int J Hematol. 2006 Apr;83(3):208-12. Review.

PMID:
16720549
11.

[How Vif regulates the infectivity of HIV-1].

Takaori-Kondo A.

Seikagaku. 2004 Dec;76(12):1569-73. Review. Japanese. No abstract available.

PMID:
15675371
12.

[Antiviral defense by APOBEC3 family proteins].

Takaori A.

Uirusu. 2005 Dec;55(2):267-72. Review. Japanese.

13.

Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more?

Carr JM, Davis AJ, Feng F, Burrell CJ, Li P.

Curr Drug Targets. 2006 Dec;7(12):1583-93. Review.

PMID:
17168833
14.

[Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].

Fan B, Cen S, Jiang JD.

Yao Xue Xue Bao. 2008 Jul;43(7):678-82. Review. Chinese.

PMID:
18819469
15.

Protecting APOBEC3G: a potential new target for HIV drug discovery.

Stopak K, Greene WC.

Curr Opin Investig Drugs. 2005 Feb;6(2):141-7. Review.

PMID:
15751736
16.

Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.

Izumi T, Shirakawa K, Takaori-Kondo A.

Mini Rev Med Chem. 2008 Mar;8(3):231-8. Review.

PMID:
18336343
17.

Death and the retrovirus.

Vartanian JP, Sommer P, Wain-Hobson S.

Trends Mol Med. 2003 Oct;9(10):409-13. Review.

PMID:
14557052
18.

[HIV-1 and ubiquitination].

Takaori-Kondo A.

Tanpakushitsu Kakusan Koso. 2006 Aug;51(10 Suppl):1433-6. Review. Japanese. No abstract available.

PMID:
16922414
19.

Interaction between HIV-1 and APOBEC3 sub-family of proteins.

Arriaga ME, Carr J, Li P, Wang B, Saksena NK.

Curr HIV Res. 2006 Oct;4(4):401-9. Review.

PMID:
17073615
20.

Virus-host interactions: role of HIV proteins Vif, Tat, and Rev.

Strebel K.

AIDS. 2003;17 Suppl 4:S25-34. Review. No abstract available.

PMID:
15080177
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk